Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have been assigned a consensus rating of “Reduce” from the five analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $3.00.
A number of equities analysts recently commented on NKTR shares. Mizuho restated a “neutral” rating and set a $6.00 target price on shares of Nektar Therapeutics in a report on Monday, August 7th. StockNews.com started coverage on Nektar Therapeutics in a research note on Thursday, August 17th. They issued a “hold” rating for the company.
Institutional Investors Weigh In On Nektar Therapeutics
Nektar Therapeutics Stock Up 11.6 %
Shares of NKTR opened at $0.65 on Tuesday. The firm’s fifty day moving average is $0.64 and its two-hundred day moving average is $0.75. The stock has a market cap of $123.58 million, a PE ratio of -0.40 and a beta of 1.00. Nektar Therapeutics has a 52-week low of $0.51 and a 52-week high of $4.37.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.03. Nektar Therapeutics had a negative return on equity of 67.03% and a negative net margin of 349.75%. The business had revenue of $20.50 million during the quarter, compared to analyst estimates of $20.94 million. During the same period in the prior year, the business earned ($0.85) earnings per share. As a group, research analysts anticipate that Nektar Therapeutics will post -0.92 earnings per share for the current year.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer.
- Five stocks we like better than Nektar Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- An Electrifying New Upgrade for Tesla Leads the Market Higher
- How to Invest in the Entertainment Industry
- Oil Jumps, 2 Plastic Stocks About To Become Value Plays
- How to Invest in Blue Chip Stocks
- The Top 5 Analysts Calls in September
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.